£125.54
0.71% yesterday
London, Oct 16, 05:45 pm CET
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock price

£125.54
+12.08 10.65% 1M
+23.71 23.29% 6M
+23.08 22.52% YTD
+7.85 6.67% 1Y
+33.02 35.69% 3Y
+52.27 71.33% 5Y
+95.08 312.19% 10Y
+113.25 921.25% 20Y
London, Closing price Thu, Oct 16 2025
-0.90 0.71%
ISIN
GB0009895292
Symbol
AZN
Industry

Key metrics

Basic
Market capitalization
£197.5b
Enterprise Value
£216.7b
Net debt
£19.2b
Cash
£5.3b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
31.9 | 18.1
P/S
4.7 | 4.4
EV/Sales
5.1 | 4.8
EV/FCF
35.5
P/B
5.9
Dividends
DPS
£2.46
Yield 1Y | 5Y
1.9% | 2.5%
Growth 1Y | 5Y
7.8% | 2.4%
Payout 1Y | 3Y
73.1% | 91.6%
Increased
1 Year
Financials (TTM | estimate)
Revenue
£42.2b | £44.7b
EBITDA
£13.2b | £16.1b
EBIT
£10.3b | £14.1b
Net Income
£6.2b | £10.8b
Free Cash Flow
£6.1b
Growth (TTM | estimate)
Revenue
15.0% | 10.8%
EBITDA
27.4% | 30.1%
EBIT
37.0% | 48.5%
Net Income
28.8% | 105.8%
Free Cash Flow
17.5%
Margin (TTM | estimate)
Gross
82.1%
EBITDA
31.3% | 35.9%
EBIT
24.4%
Net
14.7% | 24.2%
Free Cash Flow
14.5%
Financial Health
Equity Ratio
39.2%
Return on Equity
17.3%
ROCE
17.5%
ROIC
14.5%
Debt/Equity
0.7
More
EPS
£4.0
FCF per Share
£3.9
Short interest
-
Employees
94k
Rev per Employee
£430.0k
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

27x Buy
82%
6x Hold
18%

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

Buy
82%
Hold
18%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
42,184 42,184
15% 15%
100%
- Direct Costs 7,562 7,562
16% 16%
18%
34,622 34,622
15% 15%
82%
- Selling and Administrative Expenses 11,660 11,660
2% 2%
28%
- Research and Development Expense 9,843 9,843
20% 20%
23%
13,220 13,220
27% 27%
31%
- Depreciation and Amortization 2,930 2,930
2% 2%
7%
EBIT (Operating Income) EBIT 10,290 10,290
37% 37%
24%
Net Profit 6,193 6,193
29% 29%
15%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Positive
The Motley Fool
about 9 hours ago
Investing in pharmaceutical stocks can carry risks. It's not always clear which drugs will be successful and turn into blockbusters for their respective businesses.
Negative
Proactive Investors
about 15 hours ago
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) investors might want to take a deep breath. Deutsche Bank has turned bearish on the UK drugmaker, cutting its rating from Hold to Sell and trimming its price target to £105 from £110, well below the current share price of 12,548p (down 1%).
Neutral
Business Wire
one day ago
COPPELL, Texas--(BUSINESS WIRE)--AstraZeneca today announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the production of Lokelma for the benefit of patients in the United States and around the world. The investment of $445 million to expand the facility follows the groundbreaking last week at AstraZeneca's m...
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today